Leptomeningeal carcinomatosis associated with gastric cancer

Int J Clin Oncol. 2012 Aug;17(4):361-6. doi: 10.1007/s10147-011-0301-8. Epub 2011 Aug 17.

Abstract

Background: Leptomeningeal carcinomatosis (LMC) is a rare but devastating complication of gastric cancer.

Methods: The subjects were 12 gastric cancer patients who were diagnosed as having LMC at the Shizuoka Cancer Center between October 2002 and March 2009. We conducted a retrospective survey of the medical records of the study subjects and collected data on the clinical features, treatment modalities employed/outcomes, and survival of the patients.

Results: Of the 12 patients, 9 (75%) were male, and the median age was 63 years. Histopathologically, the majority of the patients (83%) had diffuse-type adenocarcinoma. At the time of diagnosis of the LMC, the other major sites of metastasis were the peritoneum (75%) and lymph nodes (50%). The median duration from the diagnosis of gastric cancer to the diagnosis of LMC was 15.6 months. While the treatment strategy changed with time, intrathecal chemotherapy (n = 10), followed by whole brain irradiation (n = 7) and subsequent ventriculo-peritoneal shunt (n = 3) was performed in 10 of the patients. Improvement of neurological functions was observed in 6 of the 10 patients. The median overall survival time from the diagnosis of LMC in all the 12 patients was 60 days. One patient survived for a considerably long period of 532 days.

Conclusions: Multidisciplinary treatment, including ventriculo-peritoneal shunt for LMC secondary to gastric cancer, may benefit selected patients, but further accumulation of clinical cases is necessary.

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / secondary
  • Adenocarcinoma* / therapy
  • Adult
  • Aged
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Meningeal Carcinomatosis* / diagnosis
  • Meningeal Carcinomatosis* / pathology
  • Meningeal Carcinomatosis* / secondary
  • Meningeal Carcinomatosis* / therapy
  • Methotrexate* / administration & dosage
  • Methotrexate* / adverse effects
  • Middle Aged
  • Retrospective Studies
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy
  • Survival Analysis
  • Ventriculoperitoneal Shunt

Substances

  • Methotrexate